Chang J, Serrano Y, Garrido R, Pedroso J, Cardoso F, García D, González D, Herrera Y, Santana D, Valdés Y, Fernández V, Vérez V

Language: Spanish
References: 19
Page: 15-21
PDF size: 244.83 Kb.

ABSTRACT

Conjugate vaccines consisting of bacterial polysaccharides linked through a covalent bond to a carrier protein have a major impact on childhood immunization schemes which have dramatically decrease the incidence of bacterial infections. In the case of Streptococcus pneumoniae more than 90 serotypes have been reported, based on the structure of the polysaccharide capsules and at least 23 of them have demonstrated clinical importance. A limited number of 7 or more recently 10 and 13 are included in licensed conjugate vaccines. On the other hand, the increasing need for these vaccines worldwide requires the incorporation of new manufacturers who are facing highly complex technology since the entire conjugation process can not affect the structural features for which the polysaccharide is immunologically recognized. Our paper provides a conjugation procedure for the capsular polysaccharide of Streptococcus pneumoniae serotype 14. The process includes fragmentation, peryodic oxidation and subsequent conjugation to tetanus toxoid or diphtheria toxoid to the polysaccharide, each intermediate was characterized by physico-chemical methods. Yields higher than 50% were obtained in all reactions. The conjugates generated high titers of IgG specific antibodies and immunological memory. In conclusion, the procedure allows immunogenic conjugates of serotype 14.

REFERENCES

1. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants. J Infect Dis 1994;170(1):76-81.

2. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152(2):361-76.

3. Vérez-Bencomo V, Fernández-Santana V, Hardy E, Toledo ME, Rodríguez A, Baly A, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;305:522–5.

4. García S, Levine OS, Cherian T, Gabastou JM, Andrus J, Working Group members. Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction. Rev Panam Salud Pública 2006;19(5):340–8.

5. Vestrheim DF, Høiby EA, Aaberge, Caugant DA. Impact of a Pneumococcal Conjugate Vaccination Program on Carriage among Children in Norway. Clin. Vaccine Immunol 2010;17(3):325-34.

6. Kellner JD. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Update on the success of the pneumococcal conjugate vaccine. Paediatr Child Health 2011;16(4):233-6.

7. WHO. Target Product Profile (TPP) for the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines. Geneva: WHO; 2008.

8. Bruckner J. Estimation of monosaccharides by the orcinolsulfuric acid reaction. Biochemical Journal 1995;60:200-5.

9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. J Biol Chem 1951;193:265-75.

10. Porro M, Vitti S, Antoni G, Neri P. Modifications of Park-Johnson ferricyanide submicromethod for the assay of reducing groups in carbohydrates. Anal Biochem 1981;118:301-6.

11. Lidenberg BJ, Lonngren D and Powell A. Structural studies on the specific type 14 pneumococcal polysaccharide. Carbohydr Res 1977;58:177-86.

12. Craig A, Ramesh K, Muys JM, Francis M, Harold J. Streptococcus pneumoniae Type 14 PolysaccharideConjugate Vaccines: Length Stabilization of Opsonophagocytic Conformational Polysaccaride Epitopes. Infect Immu 1998;66:2441-6.

13. Biemans RL, Garcon NM, Hermand PV, Poolman J, Van Mechelen MP. Pneumococcal polysaccharide conjugates vaccine. Patent 12,097,303. 2009 june 15.

14. Wang JY, Chang AH, Guttormsen HK, Rosas A, Kasper D. Construction of designer glycoconjugate vaccines with sizespecific oligosaccharide antigens and site-controlled coupling. Vaccine 2003;21:1112-7.

15. Kim JS, Laskowich ER, Michon F, Kaiser RE, Arumugham RG. Monitoring activation sites on polysaccharides by GC–MS. Anal Biochem 2006;358(1):136-42.

16. Safari D, Dekker HAT, Joosten JAF, Michalik D, Carvalho de Souza A, Adamo R, et al. Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against Streptococcus pneumonia Type 14. Infect Immun 2008;76:4615–23.

17. Che-Hung RL, Frasch CE. Polysaccharide-Protein Conjugate Vaccine. US patent 10, 566,899. 2007 jun 21.

18. Guo Z, Jennings H. Protein-Polysaccharide Conjugation. In: Pollard AJ, Maiden MCJ, eds. Meningococcal Vaccines. Methods and Protocols. Totowa, NJ: Human Press Inc; 2001. p. 49-54.

19. Moreno RL, Sampson JS, Romero-Steiner S, Wong B, Johnson SE, Ades E, et al. A murine model for the study of immune memory in response to pneumococcal conjugate vaccination. Vaccine 2004;22:3069-79.